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Abstract
Brazil is a country of continental dimensions, with many social inequalities. The latter are reflected on its health
system, which comprises a large public component called SUS, a small paid health insurance component and a
third very small private component, in which patients pay personally for medical services. Seventy five percent of
the population depends on SUS, which thus far does not provide adequate coverage for genetic medical procedures.
In 2014, SUS introduced the “Policy for the Integral Attention to Subjects with Rare Diseases”, establishing guidelines for
offering diagnosis and treatment. The policy defines the two main axes, genetic and non-genetic rare diseases. In this
fashion, public genetic services in SUS will be installed and funded not by themselves, but as part of the more general
policy of rare diseases. Unfortunately, up to now this policy is still depending on financial allowances to be effectively
launched. In this article, our intention was to describe activities developed in the area of inborn errors of metabolism
by a Brazilian reference center. In spite of the lack of support of SUS, thousands of Brazilian families affected by rare
genetic metabolic disorders, and many health professionals from all regions of Brazil, already have benefited from the
services, training programs and research projects provided by this comprehensive center.
Keywords: Brazil, Genetic Diseases, Inborn Errors of Metabolism, Rare Diseases
Background
Brazilian health system
Brazil is a federative republic with an area of 8.5 million
km2, covering 47 % of South America. With an esti-
mated population of more than 200 million individuals
in 2015, Brazil is the world’s fifth most populous coun-
try. Unfortunately, its colossal size and large population
are matched by huge regional and social inequalities.
These inequalities are reflected in the Brazilian health
system, which, as described by Paim et al. [12], is com-
posed of three subsectors: the public subsector (SUS), in
which services are financed and provided by the state at
the federal, state, and municipal levels, the private (for-
profit and non-profit) subsector, in which services are fi-
nanced in various ways with public or private funds, and
the private health insurance subsector, with different
forms of health plans, varying insurance premiums, and
tax subsidies. The private health plan and insurance
market is concentrated in the southeast region, where
61.5 % of health companies are based. According to
Paim et al. [12], 18.4 % of the population has private in-
surance and 6.1 % have insurance for civil servants.
When we were asked to write about rare disease med-
ical research and services in Brazil, we were at a cross-
roads. If we opted for describing all components of the
rare disease health system in the different cities of the
country we might end up, because of size limitations of
this article, with a confused low resolution picture, à vol
d’oiseaux. Rather than doing this, we decided to focus
on research and services offered by a reference center in
inborn errors of metabolism. We would like to make
clear that many other similar high-quality research and
service centers working on rare diseases, including on
inborn errors of metabolism, exist around the country.
However, we had no intention in being comprehensive,
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but instead chose to exemplify current practice focusing
our article on a successful and quite unique experience
in the rare disease field.
Rare disease policies of the public Brazilian health system
(SUS)
As previously mentioned, roughly 25 % of the Brazilian
population has some type of health insurance coverage.
The private health insurance companies are regulated by
the National Supplementary Health Agency (ANS), a
federal government organization established in 2000.
Guidelines for coverage of several laboratory procedures
for genetic diagnosis (genomic cytogenetics, biochemical
and molecular techniques, particularly sequencing, and
prenatal diagnostic tests) by the Insurance Companies
were issued in January 2014 [14] and although this was a
significant improvement in care, coverage is still limited
in several areas.
Yet, the vast majority of the population depends exclu-
sively on the public health system (SUS), which was cre-
ated by the Brazilian Federal Constitution in 1988 and is
organized by the Ministry of Health, with subsystems in
each Brazilian State and city. SUS is one of the largest
public health systems in the world, includes most
aspects of health care, from outpatient care to organ
transplantation, and proposes guidelines to ensure full,
universal and free-of-charge medical access for the en-
tire Brazilian population. In addition to offering appoint-
ments, medical exams and hospitalizations, SUS also
promotes immunization campaigns, prevention and
health monitoring, such as food and medication control
and medicament registration. SUS so far does not pro-
vide adequate coverage of genetic medical procedures,
with the exception of newborn screening, standard
karyotype and very few other tests.
As described by Passos-Bueno et al. [14], in 2014 SUS
introduced the “Policy for the Integral Attention to Sub-
jects with Rare Diseases” in Brazil, establishing guidelines
for offering comprehensive care (diagnosis, treatment
and/or long term management) to individuals affected by
rare diseases in the public unified health system (the same
definition of World Health Organization for rare diseases,
as those affecting less than 65 out of 100,000 individuals,
was used). This policy defines an annual plan of action
and financial and logistical support, and envisages the es-
tablishment of a national database (important for facilitat-
ing the access to high cost drugs, genetic tests, for
instance) and the creation of reference treatment centers.
These centers should be able to evaluate patients, perform
genetic testing procedures, diagnose, treat and offer gen-
etic counseling [15].
The policy defines the two main axes, genetic and
non-genetic rare diseases. In addition, it divides the gen-
etic rare diseases in 3 groups: congenital anomalies &
late-onset diseases, intellectual disability and metabolic
disorders. In this fashion, genetic services in SUS will be
installed and funded not by themselves, but as part of
the more general policy of rare diseases.
The Ministry of Health has promised to include in the
care of 15 million Brazilian patients afflicted with eight
thousand rare diseases the attendance by specialists in
reference centers, including internet, telephone and
video conference consultations [16]. Thus, at least in
paperwork, Brazil has designed a potentially appropriate
policy for dealing with rare diseases, which will finally
bring medical genetics to the public health system. Un-
fortunately, up to now, the policy has not left the printed
page and it is still depending on financial adjustments to
be effectively launched. However, considering the many
budget cuts being enforced to deal with the difficult
state of the Brazilian economy in the mid of the 2010
decade, the effective implementation of this policy may
still take a while.
Activities of a reference center in inborn errors of
metabolism
Hospital de Clínicas de Porto Alegre, located in the cap-
ital city (Porto Alegre) of the Southernmost state of
Brazil (Rio Grande do Sul), has the Medical Genetics
Service (MGS-HCPA) which is a reference center for
rare diseases well known in the continent, being recog-
nized since 2004 as WHO Collaborating Center for the
Development of Medical Genetic Services in Latin
America (WHO-CC). Among its many activities, we will
focus in the services, research and education in the area
of inborn errors of metabolism provided by MGS-
HCPA.
Brazilian networks for the investigation of inborn errors
of metabolism
The training of specialists in medical genetics in Brazil,
which started in the 1970’s and has been growing stead-
ily since then, the inclusion of genetics in the medical
practice of several specialties around the country and
the fact that the technologies for genetic analysis became
more widely available and accessible, created a demand
for information on diagnosis and management of genetic
conditions.
Nevertheless, medical specialists on rare conditions,
such as inborn errors of metabolism, are only available
in few centers around the country, usually public univer-
sity hospitals. As mentioned before, the Brazilian public
health system (SUS) does not reimburse diagnostic tests
for most genetic diseases, particularly for the inherited
metabolic conditions. Being a comprehensive genetic
service with multiple laboratories located inside a top
rank general university hospital and, due its particular
expertise in inborn errors of metabolism, the MGS-
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HCPA was receiving in the beginning of this century a
huge number of such requests for investigation of
pediatric and adult patients, coming from public and
private medical services from all Brazilian regions.
Prenatal diagnosis is restricted in Brazil, as pregnancy
interruption due to fetal disease is not legally allowed,
except cases of anencephaly. Regarding newborn screen-
ing (NBS), despite the Ministry of Health sponsoring a
program available for each Brazilian baby at no charge,
it is limited to only 6 conditions (phenylketonuria, con-
genital hypothyroidism, hemoglobin disorders, cystic fi-
brosis, biotinidase deficiency and congenital adrenal
hyperplasia), and unfortunately most of the IEMs end up
escaping newborn detection (more comprehensive NBS
programs are available to the 25 % of population which
subscribes private insurance policies).
Based in the successful experience of SIAT (Teratogen
Information System) set up at MGS-HCPA in the 1990’s,
in 2001 we decided to organize the way we deal with
these requests and set up the Information Service on
Metabolic Diseases (SIEM). When we realized that an
information service on IEM could not move forward
without diagnostic facilities available, we subsequently
created the MPS Brazil Network, the IEM Brazil Net-
work, the NPC Brazil Network, and the LSD Brazil
Network.
In the next sections, we will briefly describe these ini-
tiatives, which are maintained with public grants and
private donations, including unrestricted grants from
companies.
Each of these networks has a Coordinating Center
(headquarters, which hosts the information hub and the
main laboratory facility), Associated Centers (services
that have capability to provide comprehensive clinical
services and/or perform a limited set of tests) and Par-
ticipant Centers (any medical service that needs testing
and/or information). Their headquarters is located at the
MGS-HCPA, where is based their executive group (Gen-
eral Coordinator, Technical Staff, Operational Manager,
Administrative Manager). Important decisions are
shared with the Associated Centers, and a general meet-
ing is held at least once a year during a congress or
symposium.
The information service on metabolic diseases (SIEM)
The SIEM was created in 2001, initially as a toll-free
telephone service available to any health professional in
Brazil who was in need of information about how to ob-
tain the diagnosis in a case with suspected metabolic dis-
ease (typical questions: which tests to request? which
samples to collect? to which lab should the samples be
shipped? what specimens to obtain immediately post-
mortem?). In addition, information about emergency
management of suspected cases and a list of specialized
professionals in the geographic area could be provided
upon request. The telephone is available 24/7, with a
member of the technical staff taking the calls from Mon-
day to Friday in business hours, otherwise an answering
machine records the message and a follow-up call is
made in no more than 24–48 h. SIEM progressively
started to work more and more with electronic requests
that could be filled at the website (www.siem.ufrgs.br,
Portuguese and Spanish versions available) [4]. Until the
end of 2015, SIEM received 2,720 requests for diagnostic
help (not including requests for information and follow-
up). Of these request, 1,763 required further investiga-
tion, and a diagnosis of an inborn error of metabolism
being eventually confirmed in 264 cases (15 %).
The inborn errors of metabolism (IEM) Brazil network
The IEM Brazil Network (www.eim.ufrgs.br) was created
as a diagnostic arm of SIEM, based on a very well estab-
lished diagnostic laboratory (Wajner et al. [18]). Every
service dealing with patients with confirmed or sus-
pected metabolic diseases could become affiliated to the
IEM Brazil Network, if the patient is assisted within the
public health service (SUS). This service allowed medical
genetics, pediatrics, child neurology, among other clinics,
from all over the country, to investigate suspected patients
in a comprehensive way, with sophisticated analysis of
amino acids, organic acids, acylcarnitines, very long chain
fatty acids, and many other metabolites. Until 2015, the
IEM Brazil Network performed 73,440 tests in 19,982 pa-
tients from all 27 Brazilian states, having diagnosed 698
cases of inborn errors of metabolism. The most frequent
groups of conditions diagnosed were organic acidemias
(19 %), peroxisomal disorders (17 %), amino acid disorders
(16 %), energy metabolism disorders (13 %), carbohydrate
metabolism disorders (8 %) and urea cycle defects (6 %).
These diagnoses include many treatable conditions, em-
phasizing the importance of the SIEM-IEM Brazil Net-
work combined strategy. Figure 1 shows the geographical
distribution of the IEM Brazil network members.
The LSD Brazil network
A particular group of genetic metabolic conditions—the
lysosomal storage diseases, LSDs—has received a dispro-
portionate attention among the IEM, compared to their
relative size (there are around 60 LSDs among the 600
IEM), as specific treatments—as enzyme replacement
therapies, substrate reduction therapy and molecular
chaperones—became available for many of these condi-
tions. As the investigation for LSDs usually follows a
relatively different strategy compared to the investigation
for the other IEM, we decided to create a separate net-
work: the LSD Brazil Network (www.dld.ufrgs.br). This
network has investigated 30,576 patients until 2015, in
whom 85,613 tests were performed. The number of
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cases diagnosed in the cases referred was 1,329 (not in-
cluding mucopolysaccharidoses and Niemann-Pick type
C disease, handled by other networks as described in the
following topics). The most frequent conditions (over
than 50 cases each) were metachromatic leukodystrophy
(241 cases), Gaucher disease (197 cases), Niemann-Pick
A/B diseases (97 cases), Fabry disease (83, considering
only males) and Tay-Sachs disease (68 cases). This net-
work has been also involved in screening programs in
high-risk patients [11, 13].
The MPS Brazil network
The headquarters of the networks described in this sec-
tion is well recognized by its work in lysosomal storage
diseases and, particularly, in the mucopolysaccharidoses
(MPS), started well before ERT became available. The
huge number of requests for biochemical and genetic
testing of cases with suspected MPS led to the creation
of a separate network for this group of diseases, the
MPS Brazil Network (www.mps.ufrgs.br), which is now
well known worldwide for its diagnostic, research and
education contributions.
The MPS Brazil Network has associated centers in all
Brazilian regions and “participant centers” in all Brazilian
states. It receives around 65 requests per month for inves-
tigation of MPS, with an average of 6 new cases of MPS
diagnosed each month. The MPS Brazil network provides
a comprehensive investigation for all MPS types, and all
diagnosed cases are fully characterized in terms of bio-
chemical phenotype and genetic mutations. In addition to
the diagnostic service provided, the MPS Brazil Network
has a toll-free line to provide information for families and
health professionals, publishes a quarterly newsletter, pro-
motes educational meetings and has actions to increase
awareness in the community about MPS diseases [9]. The
data obtained in the first 1,000 patients diagnosed (30 %
MPS II, 23 % MPS VI, 20 % MPS I, 11 % MPS IV A, 7 %
MPS III B and 9 % distributed among the other MPS
types) was instrumental for the better understanding of
the MPS epidemiology in Brazil and for the planning of
preventive and management measures.
Fig. 1 Distribution of centers of the MPS Brazil Network; crosses indicate “Participant Centers”; stars indicate “Associated Centers” (at least one in
each Brazilian region, which have different colors) and the star with a circle indicate the “Coordinating Center” location
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The NPC Brazil network
As Niemann-Pick type C (NPC) disease requires for its
diagnosis an invasive technical tool, the Filipin staining
test performed in fibroblasts, we set up an independent
network to deal with the protocol to diagnose this challen-
ging disease. The NPC Brazil Network (www.ufrgs.br/
geneticahcpa/npc/) provides a comprehensive laboratory
approach, including screening tests (chitotriosidase, oxy-
sterols), diagnostic tests (Filipin), differential diagnosis (en-
zyme assays for Gaucher, Niemann-Pick A/B, acid lipase
deficiency, and others) and confirmatory genetic analysis of
NPC1 and NPC2 genes [10]. This network identified, until
the end of 2015, 75 cases of NPC disease in Brazil, coming
from all five Brazilian regions, the vast majority (96 %)
being caused by mutations in the NPC1 gene, as expected.
Research projects
The intense activity developed by the diagnostic net-
works on metabolic diseases made available a large num-
ber of samples and associated patient information. Basic
epidemiologic data became available to allow the identi-
fication of prevalent regional targets for investigation.
High numbers of patients for specific rare diseases en-
abled centers associated to these networks to develop
basic and applied research projects and to participate in
international multicenter clinical research protocols, in
addition to developing original clinical research projects
(a clinical trial to develop a innovative therapy approach
for MPS I, developed in-house, was recently approved
and funded by the Brazilian Ministry of Health).
Applied research has been also performed with the
aim of improving laboratory diagnosis, especially to
develop diagnostic protocols more suitable for devel-
oping countries, where conditions for collection and
transportation of samples are far from ideal. The in-
novative method to assay lysosomal enzymes in leuco-
cytes impregnated in filter paper is one example of
this activity [5].
Several projects aiming to better understand the basic
pathogenic mechanisms of several genetic metabolic dis-
eases are being developed, boosted by the relatively high
number of patients and samples considering that the
conditions are rare diseases. The projects involving the
study of oxidative stress pathways are one example of
this type of research activity [3] as is the project involv-
ing several Brazilian services, coordinated from Porto
Alegre, aiming to better understand the expression of
Fabry disease in females. Another example of the experi-
mental research is the one that uses in-house technology
developed with modification of mammalian cells to over-
express specific enzymes, being the cells trapped into al-
ginate capsules, which are implanted in animal models
to treat specific conditions (MPS I has been the main
target, so far) [1]. Currently, innovative techniques of
genome editing as the CRISPR-Cas9 system are being
established to treat MPS I as well.
The diagnostic activity of the networks has allowed the
identification of clusters of genetic metabolic diseases in
specific areas, which became targets for population-based
studies, developed in partnership with the Brazilian Insti-
tute of Population Medical Genetics (INAGEMP) [6].
Finally, this activity has enabled Brazil to participate in
several international multicenter clinical research proto-
cols, related to the natural history or therapy develop-
ment in rare genetic diseases This participation allowed
many Brazilian groups to develop skills and facilities for
clinical research, which eventually enabled some centers
to develop original clinical research projects and request
funding (already granted in several cases) to the Brazil-
ian Ministry of Health.
Education and training
The clinical, diagnostic and research activity developed
by the MGS-HCPA in the field of inborn errors of me-
tabolism attracted the attention of many young fellows
from Brazil and other Latin American countries, which
are looking for training opportunities in the field. This
lead to the creation of a comprehensive capacitation
program in genetic metabolic diseases, developed under
the umbrella of the WHO-CC activities. This program
provides short (1 to 3 months) and long term (12 months)
trainings, academic postgraduate courses (MSc or PhD
programs with 2 to 4 years of duration), intensive short
course and also scientific initiation opportunities. Table 1
summarizes the education and training opportunities pro-
vided by the reference center.
Concluding remarks regarding the reference center activity
on IEM
The “SIEM-Networks” combined strategy has enabled
the diagnosis of thousands of cases of inborn errors if
metabolism in Brazil since it was initially set up in 2001.
With this strategy, sophisticated laboratories and skilled
personnel located in a reference coordinating center
were made available to medical services and physicians
from all over the country, with the contribution of sev-
eral associated centers in all Brazilian regions Also, a set
of information tools (toll-free telephone, email, website,
newsletter, family oriented booklets), educational actions
(courses, symposia) and public activities were made
available to increase the awareness about these diseases
among health professionals, families and community.
Patients with treatable conditions eventually get the
treatment, in many instances by legal actions, as the
Brazilian constitution guarantees access to healthcare
for all citizens.
This model has been expanding more and more, serv-
ing as a template for new diagnostic networks in the
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metabolic (as the “MSUD Brazil Network”, for Maple
Syrup Urine Disease) and non-metabolic (as the “Rede-
BRIM—Brazilian Network for Information and Refer-
ence in Microdeletion Syndromes); [7, 8] fields. Also, the
SIEM example, in line with the older SIAT program, was
used as a template for a new information program, the
Hello Genetics (“Alô Genética”), aimed to provide infor-
mation on genetic conditions to primary health care
agents who work at community-based health centers
[17]. Table 2 summarizes the different information and
diagnostic services provided by MGS/HCPA.
Because of the intensive diagnostic activity, a signifi-
cant number of patients with very rare genetic metabolic
diseases are being identified, which has enabled the de-
velopment of several research projects. They include
studies for the development of diagnostic methods more
suitable for developing countries, for the better under-
standing of pathogenic mechanisms, for the develop-
ment of new therapeutic alternatives and also clinical
research protocols, most in association with other inter-
national centers, but some of them originally developed
by Brazilian investigators, as the treatment of MPS I
Table 2 Information and diagnostic services provided by MGS/HCPA in the field of inborn errors of metabolism
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with encapsulated modified cell overexpressing alpha-
iduronidase [1].
Genetics, genomics and rare diseases
Brazilian genetics services consist of research associated
with assistance to patients and families in a two-way
road: patients contribute to new findings, while those
findings help patients. In other words, clinical genetic
services are to be offered as part of research and utilize
funds acquired for such genetic investigations. The ana-
lysis of the description of the genetic services described
in this article shows that, in spite of so many progresses,
they maintain the same modus operandi implemented
decades ago.
Public policies for rare diseases, both in the US and in
Europe, originated from the pressure imposed by organi-
zations of patients and families affected by specific
diseases. In the US, in the 1970s, the “National
Organization for Rare Disorders (NORD)”, a private
organization, lobbied the government to create specific
laws for the development of orphan drugs, which culmi-
nated in the “Orphan Drug Act” that established incen-
tives for research on orphan drugs, including grants for
clinical trials, market exclusivity and increased patent
protection of the compounds [2]. Following the foot-
steps of this pioneer initiative, in the last two decades
other countries such as Australia (1998), the European
Union (2000) and Latin American countries like
Colombia (2010) created a series of regulations which
aimed the inclusion of rare diseases in health programs.
The vast majority of the population of Brazil depends
exclusively on the public health system (SUS), and has
still limited access to comprehensive genetic diagnosis
and treatment, since there is not yet adequate coverage
of genetic medical procedures through this system. In
2014, SUS designed “The National Policy for Rare Dis-
eases”, establishing guidelines for offering treatment to
individuals affected by rare diseases in the public unified
health system. This is an appropriate policy for dealing
with rare diseases which will finally bring medical genet-
ics to the public health system. Unfortunately, up to
now the policy has not left the printed page and it is still
depending on the availability of funds to be effectively
launched.
Conclusions
Genetics and genomics have changed the medical prac-
tice in the last years, and more dramatic changes related
to the new genetic technologies are expected to occur in
the next years. With this view, it is highly desirable that
medical genetics is formally incorporated into the health
system in Brazil, and the move of the Ministry of Health
with the national “Policy for the Integral Attention to
Subjects with Rare Diseases” is surely in the right
direction. While this does not occur, alternative ap-
proaches such as the ones developed for genetic meta-
bolic diseases, are fulfilling the important role of
providing services, promoting education and developing
research in the area of inborn errors of metabolism in
Brazil.
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